3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
3
Squamous Cell Carcinoma of Head and Neck
2
Sezary Syndrome
2
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Liver Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Interventions
Magnetic Resonance Spectroscopy
6
Dexamethasone
6
Cyclophosphamide
6
Blood Specimen Collection
6
Prednisone
5
Positron Emission Tomography Computed Tomography
4
Mammography
4
Lenalidomide
4
Colonoscopy
4
pembrolizumab
3
Tomography, X-Ray Computed
3
Surveys and Questionnaires
3
Melphalan
3
Exercise
3
Biopsy
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
weifuchun
2
obinutuzumab
2
fluciclovine F-18
2
daratumumab
2
carfilzomib
2
Preoperative Exercise
2
Positron-Emission Tomography
2
Methods
2
Magnetic Resonance Imaging
2
Injections
2
Gemcitabine
2
Educational Status
2
Doxorubicin
2
Cytarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Disease
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled